Notably, both BC models with elevated COX-2 expression in metastases had PIK3CA driver mutations, suggesting a possible therapeutic benefit of COX-2 inhibition in PI3K-altered urothelial carcinoma. This evidence concerns the gene PTGS2 and breast cancer.